Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer
Introduction Total pelvic exenteration (TPE) for clinical T4b colorectal cancer (CRC) is associated with significant morbidity. Short (0-30 days)- and intermediate (31-90 days)-term temporal analysis of complication onset is not well described, yet needed, to better counsel patients considering TPE....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748251316598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590316254789632 |
|---|---|
| author | Christopher Guske BS Nusheen Immen BS Devon Conant BS Jose Laborde PhD Joshua Linscott MD, PhD Mitchell Hayes MD Seyed Behzad Jazayeri MD Adnan Fazili MD Erin Siegel PhD, MPH Sophie Dessureault MD Julian Sanchez MD Amalia Stefanou MD Brandon Manley MD Seth Felder MD |
| author_facet | Christopher Guske BS Nusheen Immen BS Devon Conant BS Jose Laborde PhD Joshua Linscott MD, PhD Mitchell Hayes MD Seyed Behzad Jazayeri MD Adnan Fazili MD Erin Siegel PhD, MPH Sophie Dessureault MD Julian Sanchez MD Amalia Stefanou MD Brandon Manley MD Seth Felder MD |
| author_sort | Christopher Guske BS |
| collection | DOAJ |
| description | Introduction Total pelvic exenteration (TPE) for clinical T4b colorectal cancer (CRC) is associated with significant morbidity. Short (0-30 days)- and intermediate (31-90 days)-term temporal analysis of complication onset is not well described, yet needed, to better counsel patients considering TPE. Methods A retrospective cohort study of consecutive patients with primary or recurrent clinical T4b pelvic CRC undergoing open TPE between 2014 and 2023 was conducted. Clinicopathologic variables were collected for each patient. Postoperative morbidity was classified according to the Clavien-Dindo (CD) grade system and stratified by time of onset within 90 days of surgery. Pearson’s Chi-square test, Fisher’s Exact test, and the Mann-Whitney U test were used to compare primary vs recurrent patient groups, and logistic regression assessed predictors of postoperative morbidity. Statistical analysis was performed using R with two-sided significance set at <0.05. Results Twenty-seven patients were identified of which 24 (88.9%) were male with a median age of 60.4 years (interquartile range [IQR]: 56.3-70.5). Seventeen (63.0%) patients had primary disease and 10 (37.0%) had recurrent CRC. Twenty-three (85.2%) patients experienced at least one complication within 90 days of surgery, but no mortality was observed. Ten (37.0%) patients experienced a CD ≥ 3 event, of which 40% took place beyond 30 days. The most common complication overall was anemia requiring transfusion, while the most common major complication was pelvic abscess. No clinicopathologic variables analyzed were predictive of major postoperative complication within 90 days of TPE. Conclusion TPE for clinical T4b CRC carries a high risk of postoperative morbidity in both the short- and intermediate-term after surgery, with a significant proportion of complications occurring after 30 days. Given the magnitude of operation, an extended recovery with high risk for complications is common. Although a single-center series, this annotated postoperative complication profile may assist patients and clinicians when reviewing informed consent for TPE. |
| format | Article |
| id | doaj-art-357025aa13eb4d6781a667ee2516b823 |
| institution | Kabale University |
| issn | 1526-2359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj-art-357025aa13eb4d6781a667ee2516b8232025-01-24T00:03:20ZengSAGE PublishingCancer Control1526-23592025-01-013210.1177/10732748251316598Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal CancerChristopher Guske BSNusheen Immen BSDevon Conant BSJose Laborde PhDJoshua Linscott MD, PhDMitchell Hayes MDSeyed Behzad Jazayeri MDAdnan Fazili MDErin Siegel PhD, MPHSophie Dessureault MDJulian Sanchez MDAmalia Stefanou MDBrandon Manley MDSeth Felder MDIntroduction Total pelvic exenteration (TPE) for clinical T4b colorectal cancer (CRC) is associated with significant morbidity. Short (0-30 days)- and intermediate (31-90 days)-term temporal analysis of complication onset is not well described, yet needed, to better counsel patients considering TPE. Methods A retrospective cohort study of consecutive patients with primary or recurrent clinical T4b pelvic CRC undergoing open TPE between 2014 and 2023 was conducted. Clinicopathologic variables were collected for each patient. Postoperative morbidity was classified according to the Clavien-Dindo (CD) grade system and stratified by time of onset within 90 days of surgery. Pearson’s Chi-square test, Fisher’s Exact test, and the Mann-Whitney U test were used to compare primary vs recurrent patient groups, and logistic regression assessed predictors of postoperative morbidity. Statistical analysis was performed using R with two-sided significance set at <0.05. Results Twenty-seven patients were identified of which 24 (88.9%) were male with a median age of 60.4 years (interquartile range [IQR]: 56.3-70.5). Seventeen (63.0%) patients had primary disease and 10 (37.0%) had recurrent CRC. Twenty-three (85.2%) patients experienced at least one complication within 90 days of surgery, but no mortality was observed. Ten (37.0%) patients experienced a CD ≥ 3 event, of which 40% took place beyond 30 days. The most common complication overall was anemia requiring transfusion, while the most common major complication was pelvic abscess. No clinicopathologic variables analyzed were predictive of major postoperative complication within 90 days of TPE. Conclusion TPE for clinical T4b CRC carries a high risk of postoperative morbidity in both the short- and intermediate-term after surgery, with a significant proportion of complications occurring after 30 days. Given the magnitude of operation, an extended recovery with high risk for complications is common. Although a single-center series, this annotated postoperative complication profile may assist patients and clinicians when reviewing informed consent for TPE.https://doi.org/10.1177/10732748251316598 |
| spellingShingle | Christopher Guske BS Nusheen Immen BS Devon Conant BS Jose Laborde PhD Joshua Linscott MD, PhD Mitchell Hayes MD Seyed Behzad Jazayeri MD Adnan Fazili MD Erin Siegel PhD, MPH Sophie Dessureault MD Julian Sanchez MD Amalia Stefanou MD Brandon Manley MD Seth Felder MD Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer Cancer Control |
| title | Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer |
| title_full | Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer |
| title_fullStr | Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer |
| title_full_unstemmed | Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer |
| title_short | Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer |
| title_sort | short and intermediate term morbidity following total pelvic exenteration in colorectal cancer |
| url | https://doi.org/10.1177/10732748251316598 |
| work_keys_str_mv | AT christopherguskebs shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT nusheenimmenbs shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT devonconantbs shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT joselabordephd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT joshualinscottmdphd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT mitchellhayesmd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT seyedbehzadjazayerimd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT adnanfazilimd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT erinsiegelphdmph shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT sophiedessureaultmd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT juliansanchezmd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT amaliastefanoumd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT brandonmanleymd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer AT sethfeldermd shortandintermediatetermmorbidityfollowingtotalpelvicexenterationincolorectalcancer |